Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Alnylam Pharma (0HD2) Share Price & Analysis

4 Followers

0HD2 Stock Chart & Stats

$151.99-$4.90(-2.70%)
At close: 4:30 PM GMT
$150$200$250Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$149.30 - $158.82
52-Week Range
$149.30 - $477.82
Previous Close
$156.20
Volume
N/A
Average Volume (3M)
784
Market Cap
$20.31B
Enterprise Value
$33.47B
Total Cash (Recent Filing)
$3.59B
Total Debt (Recent Filing)
$1.26B
Price to Earnings (P/E)
7.4
Beta
0.63
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
1.72
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

TTR Franchise Growth

Rapid TTR revenue growth shows strong commercial traction for Alnylam’s marketed franchise and expanding demand in ATTR cardiomyopathy. Continued uptake provides a durable revenue base, while scale can support investment in additional RNAi medicines and broader patient access.

RNAi Clinical And Commercial Differentiation

Clinical outcome evidence and a convenient quarterly dosing profile strengthen AMVUTTRA’s differentiation in a serious rare disease. These characteristics can support physician adoption, patient persistence, and the company’s ability to build a lasting position in TTR treatment.

Cash Generation And Financial Capacity

Strong operating and free cash flow gives Alnylam internal funding capacity for clinical development, commercialization, and pipeline expansion. Free cash flow representing about 86% of net income also supports the durability of the current profitability inflection and strategic flexibility.

Bears Say

Slower AMVUTTRA Patient Conversion

Slower conversion of physician interest into patient starts may delay the realization of AMVUTTRA’s commercial opportunity. If newer prescribers remain less familiar with ATTR-CM or have limited eligible patients, growth investment may produce a more gradual and costly ramp.

Margin And Collaboration Revenue Pressure

Higher royalty costs are reducing product gross margin, while collaboration revenue can be volatile after a prior one-time Roche milestone. This mix creates pressure on earnings quality and makes reported operating performance more dependent on product scale and recurring sales.

Commercial Leadership Transition

A change in commercial leadership adds execution risk while Alnylam is still working to improve AMVUTTRA conversion and prepare future launches. Transition time could disrupt accountability or go-to-market momentum, even though the existing organization provides a foundation for continuity.

Alnylam Pharma News

0HD2 FAQ

What was Alnylam Pharma’s price range in the past 12 months?
Alnylam Pharma lowest share price was $149.30 and its highest was $477.82 in the past 12 months.
What is Alnylam Pharma’s market cap?
Alnylam Pharma’s market cap is $20.31B.
When is Alnylam Pharma’s upcoming earnings report date?
Alnylam Pharma’s next earnings report is estimated for Feb 18, 2027 (not yet confirmed), which is in 99 days.
How were Alnylam Pharma’s earnings last quarter?
Alnylam Pharma released its earnings results on Oct 29, 2026. The company reported $15.72 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.06.
Is Alnylam Pharma overvalued?
According to Wall Street analysts Alnylam Pharma’s price is currently Undervalued.
Does Alnylam Pharma pay dividends?
Alnylam Pharma pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Alnylam Pharma dividends here
What is Alnylam Pharma’s EPS estimate?
Alnylam Pharma’s EPS estimate is 1.72.
How many shares outstanding does Alnylam Pharma have?
Alnylam Pharma has 133,937,580 shares outstanding.
What happened to Alnylam Pharma’s price movement after its last earnings report?
Alnylam Pharma reported an EPS of $15.72 in its last earnings report, beating expectations of $1.66. Following the earnings report the stock price went down -22.275%.
Which hedge fund is a major shareholder of Alnylam Pharma?
Hedge funds hold Alnylam Pharma shares: the largest hedge-fund position in Alnylam Pharma is 909,503,438 shares, and hedge funds decreased their holdings by 25.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology